Cochrane · systematic review · CD001016
Cyclical progestogens for heavy menstrual bleeding
Bofill Rodriguez, M, Lethaby, A, Low, C, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 5 · 41.7%Low 5 · 41.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding
Population: women with heavy menstrual bleeding
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Menstrual blood loss Progestogen therapy (luteal phase only) vs other medical therapy | no estimate extracted | 4 studies · 145 participants | Low Downgraded: inconsistency |
Satisfaction Progestogen therapy (luteal phase only) vs other medical therapy | OR 0.8 [0.17, 3.8] | 1 study · 52 participants | Very low Downgraded: risk of bias |
Days of bleeding Progestogen therapy (luteal phase only) vs other medical therapy | no estimate extracted | 5 studies · 171 participants | Very low Downgraded: inconsistency |
Quality of life Physical functioning Progestogen therapy (luteal phase only) vs other medical therapy | no estimate extracted | 1 study · 62 participants | Very low Downgraded: risk of bias |
Total adverse effects Progestogen therapy (luteal phase only) vs other medical therapy | OR 0.68 [0.36, 1.28] | 5 studies · 197 participants | Very low Downgraded: risk of bias |
Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding
Population: women with heavy menstrual bleeding
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Menstrual blood loss PBAC after 3 months Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | no estimate extracted | 4 studies · 355 participants | Very low Downgraded: risk of bias |
Menstrual blood loss PBAC after 6 months Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | no estimate extracted | 1 study · 76 participants | Low Downgraded: risk of bias |
Satisfaction Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | OR 0.31 [0.13, 0.71] | 1 study · 95 participants | Low Downgraded: risk of bias |
Days of bleeding Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | no estimate extracted | NR | No studies |
Quality of life Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | no estimate extracted | NR | No studies |
Adverse effect Headache Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | OR 1.45 [0.4, 5.31] | 2 studies · 189 participants | Low Downgraded: risk of bias |
Adverse effect Breakthrough bleeding/spotting Progestogen therapy long cycle (3 to 4 weeks) vs other medical therapy | OR 0.18 [0.06, 0.55] | 3 studies · 220 participants | Low Downgraded: risk of bias |